recent
demand
nanoparticul
product
virus
plasmid
protein
nanoparticl
drug
deliveri
system
result
requir
predict
control
product
process
protein
nanoparticl
attract
candid
gene
molecular
therapi
due
rel
easi
product
manipul
particl
combin
advantag
viral
nonvir
vector
minim
disadvantag
howev
success
applic
depend
avail
select
scalabl
methodolog
product
recoveri
purif
downstream
process
nanoparticl
depend
product
process
produc
system
cultur
media
structur
natur
assembl
nanoparticl
ie
mainli
size
shape
architectur
paper
common
process
current
use
purif
nanoparticl
review
entir
dna
sequenc
human
genom
identif
character
human
gene
lead
understand
sever
human
diseas
normal
aberr
gene
play
import
role
develop
provid
sever
opportun
interfer
diseas
process
deliv
protein
pharmacolog
agent
genet
materi
target
cell
affect
diseas
approach
target
diseas
design
molecular
therapi
like
play
increasingli
import
role
medicin
throughout
centuri
gene
therapi
particular
approach
molecular
therapi
nucleic
acid
deliv
control
genet
flow
first
human
gene
therapi
phase
trial
carri
correct
ada
adenosin
deaminas
enzym
scid
sever
combin
immunodefici
diseas
patient
sinc
signific
advanc
experienc
field
human
gene
therapi
driven
increas
knowledg
understand
molecular
mechan
diseas
well
advanc
vector
design
technolog
produc
effect
effici
safer
deliveri
vector
sinc
one
thousand
gene
therapi
clinic
trial
conduct
worldwid
treatment
sever
diseas
wwwwileycoukgenetherapyclin
cancer
main
target
total
approv
clinic
trial
target
gene
therapi
clinic
trial
includ
cardiovascular
patholog
monogen
diseas
infecti
diseas
among
other
molecular
therapi
requir
intracellular
deliveri
biolog
activ
compound
due
rapid
elimin
circul
widespread
deliveri
nontarget
organ
tissu
biolog
need
administr
larg
quantiti
often
econom
unfeas
may
lead
sever
complic
owe
product
toxic
vivo
deliveri
also
complex
process
involv
passag
differ
biolog
barrier
includ
cell
membran
lipophil
natur
restrict
direct
intracellular
deliveri
potenti
therapeut
bottleneck
driven
research
develop
novel
molecular
deliveri
vector
associ
product
technolog
mainli
aim
improv
safeti
efficaci
first
gener
molecular
therapi
vector
explor
abil
viral
system
deliv
mostli
genet
inform
eukaryot
cell
order
regul
cellular
function
express
therapeut
protein
even
though
viral
vector
still
popular
deliveri
system
use
laboratori
studi
clinic
trial
sever
disadvantag
associ
vector
includ
possibl
advers
immun
respons
random
insert
genom
advantag
disadvantag
main
deliveri
system
use
molecular
therapi
summar
tab
nonvir
deliveri
system
sever
advantag
viral
vector
system
includ
liposom
dnaprotein
polymer
complex
construct
less
immunogen
order
enabl
repeat
administr
rel
low
titer
pfuml
tabl
continu
next
page
oret
limit
size
express
cassett
use
drug
deliveri
system
produc
chemic
defin
compon
howev
number
obstacl
eg
lack
specif
target
low
transfect
effici
transient
express
limit
applic
nonvir
base
vector
molecular
therapi
approach
tab
ideal
deliveri
vector
one
combin
advantag
viral
nonvir
vector
minim
disadvantag
viruslik
particl
vlp
bionanoparticl
mainli
compos
structur
protein
viru
usual
lack
correspond
genet
materi
produc
recombin
express
viral
structur
protein
selfassembl
nanostructur
ident
nativ
virus
noninfecti
vlp
similar
structur
tropism
natur
viru
deriv
demonstr
compar
cellular
uptak
intracellular
traffick
vlp
attract
candid
prophylact
vaccin
genet
molecular
therapi
sinc
rel
easi
produc
manipul
howev
success
applic
depend
avail
select
scalabl
method
product
recoveri
purif
integr
effect
upstream
product
step
paper
review
common
downstream
process
method
suitabl
purif
vlp
one
strike
featur
vlp
extrem
diversif
term
structur
architectur
product
system
date
vlp
produc
thirti
differ
virus
differ
type
engin
product
system
includ
yeast
eg
saccharomyc
cerevisia
pichia
pastori
bacteria
eg
escherichia
coli
staphylococcu
aureu
insect
cell
eg
drosophila
cell
spodoptera
frugiperda
high
five
mammalian
cell
eg
hek
vero
hela
human
te
fli
mdck
bhk
insect
larva
plant
eg
banana
musa
spp
binari
vector
crustac
eg
crayfish
shrimp
despit
differ
structur
architectur
product
system
methodolog
use
purif
vlp
vari
around
oper
outlin
fig
figur
common
methodolog
use
downstream
process
purifi
bionanoparticl
base
centrifugationprecipit
process
membran
oper
chromatographi
purif
downstream
process
vlp
depend
product
process
importantli
produc
system
cultur
media
vlp
architectur
similar
biolog
molecular
therapi
purif
vlp
specif
concern
relat
structur
natur
assembl
nanoparticl
mainli
size
shape
architectur
produc
celllin
deriv
impur
well
produc
media
addit
serum
need
remov
meet
qualiti
approv
standard
regulatori
agenc
gener
rule
thumb
establish
purif
process
recombin
protein
may
appli
downstream
process
vlp
particular
initi
oper
aim
remov
abund
impur
contamin
select
higher
volumetr
capac
throughput
final
purif
step
aim
remov
structur
similar
molecul
assembl
select
high
select
unit
oper
lower
volumetr
capac
throughput
fig
typic
initi
step
aim
separ
cultur
media
produc
cell
product
concentr
condit
fig
microfiltr
diafiltr
oper
gener
select
stage
purif
stage
process
see
fig
involv
highli
select
oper
tradit
ultracentrifug
recent
chromatographi
order
remov
impur
purifi
assembl
vlp
high
puriti
standard
final
stage
process
polish
stage
aim
polish
concentr
product
stage
oper
must
select
enabl
addit
tight
control
misassembl
particl
particl
similar
size
although
differ
final
architectur
biomolecul
select
downstream
process
oper
purifi
nanoparticl
highli
depend
properti
natur
nanoparticl
stabil
product
process
instanc
depend
type
nativ
viru
eg
adenoviru
retroviru
etc
vlp
releas
cultur
media
produc
cell
cultur
remain
solubl
compartment
insid
produc
cell
line
releas
particl
easili
separ
produc
cell
simpl
lowspe
centrifug
recoveri
nonreleas
particl
preced
cell
lysi
process
similar
choic
usual
made
compar
recoveri
excret
versu
nonexcret
protein
releas
nanoparticl
produc
cell
line
confer
addit
concern
regard
product
properti
stabil
regard
overal
properti
releas
nanoparticl
involv
lipid
bilay
render
outermost
surfac
particl
neg
charg
sinc
surfac
present
thu
target
purif
oper
difficult
distinguish
nanoparticl
impur
contain
similar
outer
surfac
cellular
vesicl
relev
exampl
lipid
bilay
releas
nanoparticl
also
labil
overal
particl
becom
sensibl
shear
osmot
pressur
temperatur
ph
ionic
strength
variat
degrad
nanoparticl
may
inher
major
purif
oper
result
gener
impur
similar
characterist
product
thu
anoth
critic
issu
consid
design
nanoparticl
purif
process
despit
differ
method
avail
recov
crude
sampl
desir
nanoparticl
differ
product
system
methodolog
use
purif
vlp
vari
around
oper
mostli
base
centrifugationprecipit
process
membran
oper
chromatographi
purif
fig
criteria
use
select
appropri
method
viral
concentr
purif
includ
capabl
process
larg
volum
viral
prepar
high
yield
preserv
stabil
particl
produc
eas
process
scaleup
low
cost
oper
final
qualiti
standard
protein
purif
precipit
effici
simpl
method
purifi
nanoparticl
tab
precipit
mechan
interpret
protein
solut
least
qualit
basi
basi
theori
derjaguin
landau
verweey
overbeek
dlvo
defin
stabil
dispers
dlvo
theori
view
stabil
dispers
particl
determin
simpl
alg
figur
rule
thumb
object
differ
stage
bionanoparticl
purif
process
sequenc
unit
oper
follow
decreas
capac
throughput
increas
select
unit
oper
higher
volumetr
capac
throughput
select
oper
closer
bioreactor
initi
step
purif
process
final
purif
step
criteria
involv
select
highli
select
unit
oper
lower
volumetr
capac
throughput
braic
sum
potenti
energi
lead
repuls
electrostat
natur
associ
diffus
doubl
layer
surround
charg
particl
surfac
ionic
solut
potenti
energi
lead
attract
aris
van
der
waal
forc
hydrophob
interact
accord
dlvo
theori
nanoparticl
maintain
solut
total
repuls
potenti
higher
total
attract
potenti
dlvo
theori
net
balanc
attract
repuls
potenti
energi
depend
surfac
potenti
dielectr
constant
ionic
strength
medium
strength
van
der
waal
forc
dispers
stabil
normal
associ
presenc
surfac
layer
adsorb
ion
destabil
addit
neutral
salt
chang
dielectr
constant
modifi
surfac
potenti
particl
andor
chang
balanc
charg
versu
hydrophob
region
whilst
detail
quantit
applic
dlvo
theori
critic
present
sever
limit
regard
applic
protein
solut
theori
offer
simpl
descript
approach
understand
particleparticl
interact
effect
dispers
stabil
salt
polym
tab
use
precipit
agent
promot
precipit
nanoparticl
keep
impur
solubil
solut
saltingout
type
precipit
nanoparticl
achiev
ad
ammonium
sulfat
concentr
mechan
similar
saltingout
protein
precipit
nanoparticl
explor
higher
hydrophob
charact
protein
assembl
nanoparticl
compar
individu
protein
molecul
therefor
nanoparticl
precipit
achiev
lower
concentr
ammonium
sulfat
typic
tab
precipit
volum
exclus
effect
use
peg
polym
also
use
purif
protein
nanoparticl
tab
case
protein
precipit
increas
effect
peg
size
polym
increas
document
systemat
studi
protein
nanoparticl
precipit
scarc
clear
tendenc
observ
tab
addit
similar
addit
salt
protein
nanoparticl
precipit
lower
polym
concentr
compar
nonassembl
protein
molecul
typic
rang
wv
purif
factor
maxim
optim
precipit
condit
mostli
regard
precipit
agent
concentr
temperatur
reaction
time
purif
precipit
select
oper
coprecipit
impur
polym
along
protein
nanoparticl
loss
nativ
activ
possibl
due
chang
osmot
pressur
limit
use
method
use
centrifug
base
method
protein
nanoparticl
purif
origin
virolog
studi
nativ
virus
viral
particl
purifi
basi
size
densiti
protocol
base
ultracentrifug
densiti
gradient
method
first
adapt
integr
protein
nanoparticl
purif
therapeut
use
process
separ
achiev
base
agent
commonli
use
gener
densiti
gradient
even
though
media
colloid
silica
percol
nycodenz
iodixanol
also
success
use
purifi
viral
particl
although
wide
use
ultracentrifug
method
timeconsum
difficult
scale
recoveri
small
mainli
due
particl
degrad
occur
upon
pressur
forc
osmot
shock
addit
copurif
contamin
deriv
cultur
media
pack
cell
line
membran
cell
vesicl
releas
cultur
medium
may
also
occur
moreov
prepar
densiti
gradient
requir
technic
expertis
timeconsum
sever
practic
disadvantag
regard
manipul
densiti
gradient
agent
case
recoveri
yield
small
mostli
due
high
sensit
protein
nanoparticl
assembl
osmot
pressur
fact
viscou
hyperosmot
natur
commonli
use
densiti
gradient
gener
agent
eg
saccharos
caesium
chlorid
togeth
high
shear
forc
gener
centrifug
forc
field
contribut
disrupt
integr
function
assembl
protein
nanoparticl
even
though
isoosmot
media
colloid
silica
percol
nycodenz
iodoxanol
success
use
address
disadvantag
evid
preserv
integr
function
viral
particl
use
ultracentrifugationbas
method
largescal
purif
protein
nanoparticl
still
limit
nevertheless
ultracentrifug
effect
analyt
tool
character
assembl
nanoparticl
enabl
estim
nanoparticl
size
architectur
mass
densiti
andor
diffus
membran
separ
process
frequent
use
biotechnolog
industri
separ
compon
fluid
stream
basi
hydrodynam
radiu
differ
membran
wide
rang
pore
diamet
commerci
avail
make
membran
separ
versatil
oper
use
media
clarif
product
concentr
buffer
exchang
steril
filtrat
membran
oper
particularli
suitabl
protein
nanoparticl
purif
number
publish
nanoparticl
purif
process
use
membran
oper
increas
membran
use
differ
object
tab
summar
exampl
viral
nanoparticl
purif
process
use
membran
oper
membran
nomin
pore
size
lm
use
microfiltr
oper
typic
clarifi
product
stream
remov
insolubl
particul
materi
typic
produc
cell
cell
fragment
retain
membran
product
goe
across
membran
recov
permeat
stream
contrast
centrifug
microfiltr
gener
particlefre
harvest
solut
requir
addit
clarif
subsequ
purif
hand
use
membran
low
nomin
pore
size
typic
nanomet
scale
enabl
product
concentr
ultrafiltr
membran
usual
rate
nomin
molecular
weight
cutoff
molecular
weight
globular
protein
retain
membran
ultrafiltr
membran
select
ensur
reject
product
interest
permeat
impur
therefor
product
concentr
insid
membran
recov
retent
stream
ultrafiltr
membran
also
use
buffer
exchang
ad
buffer
membran
feed
reservoir
diafiltr
even
though
suitabl
protein
nanoparticl
recoveri
major
disadvantag
membran
separ
concern
membran
fowl
accord
hagenpoiseuil
equat
transmembran
pressur
differ
permeat
flux
depend
mostli
membran
nomin
pore
size
viscos
stream
higher
flux
achiev
larger
pore
lower
viscos
larger
concentr
factor
achiev
membran
smaller
pore
size
howev
higher
concentr
factor
associ
higher
viscos
result
lower
permeat
flux
addit
concentr
polar
membran
also
increas
increas
retent
concentr
also
lead
lower
flux
select
membran
nomin
pore
size
also
depend
natur
composit
feed
stream
impur
contamin
hydrodynam
radii
similar
product
copurifi
coconcentr
mostli
due
nonselect
membran
addit
particularli
regard
viral
nanoparticl
recent
shown
grzenia
et
al
membran
oper
perform
affect
media
composit
work
author
observ
decreas
permeat
flux
upon
switch
cell
growth
media
serumfre
media
even
though
clear
explan
advanc
observ
advis
develop
cell
cultur
membran
purif
parallel
upon
select
membran
nomin
pore
size
similar
product
degre
fraction
achiev
purif
viral
particl
correctli
assembl
misassembl
particl
protein
aggreg
disrupt
particl
membran
protein
aggreg
cell
vesicl
despit
disadvantag
point
use
membran
process
gain
increas
import
viral
nanoparticl
product
process
membran
use
microfiltr
strategi
media
clarif
particl
concentr
ultrafiltr
strategi
possibl
fraction
buffer
exchang
diafiltr
strategi
membran
process
easili
scaledup
use
cgmp
manufactur
process
addit
advantag
membran
process
abil
process
integr
shown
subramanian
et
al
close
membran
system
success
scaledup
purif
adenovir
particl
system
effect
recov
purifi
concentr
intracellular
extracellular
virus
integr
cell
lysi
membran
modul
particl
recoveri
achiev
concentr
factor
process
time
less
h
chromatographi
becom
popular
methodolog
downstream
process
sinc
facilit
high
recoveri
rate
high
puriti
product
moreov
easi
scale
offer
good
platform
larg
scale
product
methodolog
also
appli
purif
nanoparticul
materi
gene
therapi
vector
tab
chromatograph
system
use
purif
vlp
nanoparticul
materi
must
take
account
larg
diamet
ie
usual
nm
special
resin
chosen
overcom
low
bind
effici
capac
tradit
resin
mostli
due
surfac
adsorpt
pore
exclus
effect
fact
current
avail
chromatograph
matric
pore
within
nm
diamet
design
maxim
adsorpt
protein
macromolecul
rather
virus
adsorpt
nanoparticul
materi
restrict
bead
surfac
area
contamin
protein
access
area
insid
pore
lead
poor
select
low
resolut
low
yield
adsorb
kda
mwco
omega
polyethersulfon
membran
disc
filterpal
gelman
scienc
sequenti
microfiltr
ultradiafiltr
process
use
clarif
concentr
partial
purif
retrovir
particl
crude
supernat
order
circumv
problem
found
convent
chromatographi
support
novel
chromatographi
approach
aim
optim
adsorpt
condit
maxim
bind
capac
product
recoveri
develop
membran
monolith
gain
particular
relev
altern
porou
support
monolith
continu
bed
consist
singl
piec
highli
porou
materi
character
interconnect
network
channel
lm
diamet
prepar
varieti
shape
dimens
use
rel
straightforward
polymer
chemistri
derivat
tradit
chromatographi
ligand
consequ
macropor
structur
materi
mass
transport
mainli
base
convect
overcom
pore
diffusion
issu
encount
classic
porou
bead
larg
poros
support
lead
higher
nanoparticl
access
ligand
locat
insid
monolith
channel
tabl
differ
resin
use
interact
sizeexclus
chromatographi
purif
viruslik
particl
respect
recoveri
rate
tabl
continu
next
page
low
pressur
drop
character
monolith
oper
addit
advantag
enabl
use
high
flow
rate
thu
lead
higher
throughput
compar
tradit
bead
matrix
membran
absorb
also
develop
nanoparticul
materi
purif
similar
monolith
column
adsorpt
membran
reflect
technolog
advanc
liquidchromatographi
base
favor
hydrodynam
interact
target
molecul
activ
site
membran
occur
convect
flowthrough
pore
thu
membran
unit
also
maintain
high
effici
high
flow
rate
well
use
larg
molecul
low
diffus
tentacl
support
offer
possibl
increas
viru
bind
capac
advantag
use
support
steric
access
ligand
avail
viru
captur
due
presenc
inert
flexibl
spacer
arm
separ
ligand
resin
surfac
therefor
larg
particl
attain
access
otherwis
steric
inaccess
bind
site
addit
sinc
longer
exclus
base
surfac
chromatograph
bead
larger
amount
ligand
avail
bind
even
disadvantag
tradit
support
chromatographi
wide
use
nanoparticl
purif
summar
tab
interact
chromatographi
mode
eg
ionexchang
chromatographi
immobil
metal
affin
chromatographi
hydrophob
interact
chromatographi
well
size
exclus
chromatographi
suitabl
purif
vlp
sever
literatur
studi
outlin
practic
strategi
product
purif
bionanoparticl
small
size
viral
genom
eas
viruslik
particl
produc
serum
free
medium
ultrahydrogel
water
doublelay
rotaviruslik
particl
manipul
simplic
purif
process
make
protein
cage
attract
altern
transgen
system
display
antigen
protein
wide
clinic
applic
vector
gene
therapi
depend
avail
effici
largescal
manufactur
procedur
signific
advanc
downstream
process
viral
vector
made
recent
year
variou
select
chromatographi
matric
identifi
new
chromatographi
technolog
better
suit
viru
purif
purpos
develop
promis
result
uniqu
perfect
purif
method
cover
broad
rang
nanoparticul
product
biotechnolog
andor
biomed
interest
current
research
laboratori
industri
deal
mechan
choos
best
approach
purif
bionanoparticl
interest
suitabl
downstream
process
take
account
product
type
size
product
sourc
well
final
recoveri
yield
advanc
altern
downstream
process
technolog
like
base
develop
new
materi
eg
smarter
polym
new
ligand
product
engin
new
approach
process
integr
aim
tighter
coupl
upstream
downstream
process
